Ibsrela (Tenapanor HCl) Patent Expiration, LOE Window & CMS Spending

Ibsrela (Tenapanor HCl) by Ardelyx: FDA Orange Book core substance LOE 2033-08-01 (last listed 2042-11-26), 0 AB generics, $101.4M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorArdelyx
FDA Application & PathwayN211801 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-08-01
Last Listed Patent or Exclusivity Date2042-11-26
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$101.4M
2024 Medicare Part D Spend$68.4M
2024 Medicaid Spend$33.0M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 20.2% 2-yr change)